NCT03678883 2024-11-07
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
University of Nebraska
Milton S. Hershey Medical Center
University of Southern California
Heidelberg University
The Alvin and Lois Lapidus Cancer Institute